DexCom (DXCM) PT Raised to $125 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Wall Street ends sharply higher as AI optimism reignites and Treasury yields retreat
DexCom (DXCM) PT Raised to $130 at Morgan Stanley
August 3, 2018 7:46 AM EDTMorgan Stanley raised its price target on DexCom (NASDAQ: DXCM) to $130.00 (from $70.00) while maintaining a Equalweight rating.
... MoreDexCom (DXCM) PT Raised to $125 at BMO Capital
August 2, 2018 8:58 AM EDTBMO Capital raised its price target on DexCom (NASDAQ: DXCM) to $125.00 (from $112.00) while maintaining a Outperform rating.
... MoreDexCom (DXCM) PT Raised to $120 at Cowen Following 'Monster' Qtr
August 2, 2018 7:59 AM EDTCowen raised its price target on DexCom (NASDAQ: DXCM) to $120.00 (from $110.00) while maintaining a Outperform rating following its "huge" beat and raise.
Analyst Doug Schenkel commented, "DXCM posted a huge beat and raise. Deals with payers to expand access / simplify distribution could temper... More
DexCom (DXCM) PT Raised to $125 at Jefferies
August 2, 2018 5:14 AM EDTJefferies raised its price target on DexCom (NASDAQ: DXCM) to $125.00 (from $115.00) while maintaining a Buy rating.
... MoreDexCom (DXCM) Tops Q2 EPS by 8c
August 1, 2018 5:04 PM EDTDexCom (NASDAQ: DXCM) reported Q2 EPS of ($0.10), $0.08 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $242.5 million versus the consensus estimate of $205.68 million.
GUIDANCE:
DexCom sees FY2018 revenue of $925 million, versus the consensus of $862.2 million.
For earnings history and earnings-related data on DexCom (DXCM) click here.
... More